Cigna issues positive coverage decision for NanoString's Prosigna(R) breast cancer assay
NanoString announced that Cigna has issued a positive Medical Coverage Policy decision for the Prosignaź Breast Cancer Gene Signature Assay. Cigna and its roughly 13 million members join other payors now covering Prosigna, representing more than 135 million covered lives throughout the U.S. May 26, 2016